Monimus Capital Management LP Buys Shares of 7,296 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Monimus Capital Management LP purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,296 shares of the medical equipment provider's stock, valued at approximately $653,000.

Other large investors also recently added to or reduced their stakes in the company. State of New Jersey Common Pension Fund D boosted its position in shares of Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock valued at $2,364,000 after acquiring an additional 115 shares during the last quarter. Bleakley Financial Group LLC raised its stake in Lantheus by 6.1% in the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock valued at $200,000 after purchasing an additional 129 shares in the last quarter. Avantax Advisory Services Inc. lifted its position in Lantheus by 5.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock valued at $213,000 after purchasing an additional 132 shares during the last quarter. UMB Bank n.a. grew its stake in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after buying an additional 134 shares in the last quarter. Finally, Aurora Investment Counsel lifted its holdings in shares of Lantheus by 0.8% during the 4th quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider's stock worth $1,718,000 after acquiring an additional 146 shares during the last quarter. Institutional investors own 99.06% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several brokerages have recently commented on LNTH. JMP Securities reiterated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial upped their target price on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. The Goldman Sachs Group started coverage on Lantheus in a research report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price for the company. Finally, StockNews.com lowered Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, Lantheus presently has a consensus rating of "Moderate Buy" and an average price target of $132.86.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 54,109 shares of company stock worth $5,105,606 over the last quarter. Insiders own 1.50% of the company's stock.

Lantheus Trading Up 1.0 %

Lantheus stock traded up $1.06 during midday trading on Wednesday, hitting $103.28. The stock had a trading volume of 505,639 shares, compared to its average volume of 937,125. Lantheus Holdings, Inc. has a 52-week low of $56.52 and a 52-week high of $126.89. The company has a market capitalization of $7.07 billion, a PE ratio of 17.18 and a beta of 0.38. The firm's fifty day moving average is $92.35 and its two-hundred day moving average is $96.64.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. As a group, equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.